These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 11256420)

  • 1. The alloresponse.
    Hernandez-Fuentes MP; Baker RJ; Lechler RI
    Rev Immunogenet; 1999; 1(3):282-96. PubMed ID: 11256420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indirect allorecognition in solid organ transplantation.
    Harris PE; Cortesini R; Suciu-Foca N
    Rev Immunogenet; 1999; 1(3):297-308. PubMed ID: 11256421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rejection mechanisms in transplantation.
    Game DS; Warrens AN; Lechler RI
    Wien Klin Wochenschr; 2001 Oct; 113(20-21):832-8. PubMed ID: 11732119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerogenic response: allorecognition pathways.
    Caballero A; Fernandez N; Lavado R; Bravo MJ; Miranda JM; Alonso A
    Transpl Immunol; 2006 Dec; 17(1):3-6. PubMed ID: 17157204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presentation of donor major histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates allograft rejection.
    Pêche H; Heslan M; Usal C; Amigorena S; Cuturi MC
    Transplantation; 2003 Nov; 76(10):1503-10. PubMed ID: 14657694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How T cells recognize alloantigen: evidence for two pathways of allorecognition.
    Watschinger B
    Nephrol Dial Transplant; 1995; 10(9):1556-8. PubMed ID: 8559468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow-derived immature dendritic cells prime in vivo alloreactive T cells for interleukin-4-dependent rejection of major histocompatibility complex class II antigen-disparate cardiac allograft.
    Buonocore S; Flamand V; Goldman M; Braun MY
    Transplantation; 2003 Feb; 75(3):407-13. PubMed ID: 12589166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK cells contribute to the skin graft rejection promoted by CD4+ T cells activated through the indirect allorecognition pathway.
    Ito A; Shimura H; Nitahara A; Tomiyama K; Ito M; Kanekura T; Okumura K; Yagita H; Kawai K
    Int Immunol; 2008 Oct; 20(10):1343-9. PubMed ID: 18697765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New spectrum of allorecognition pathways: implications for graft rejection and transplantation tolerance.
    Jiang S; Herrera O; Lechler RI
    Curr Opin Immunol; 2004 Oct; 16(5):550-7. PubMed ID: 15341998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The replacement of graft endothelium by recipient-type cells conditions allograft rejection mediated by indirect pathway CD4(+) T cells.
    Kapessidou Y; Habran C; Buonocore S; Flamand V; Barvais L; Goldman M; Braun MY
    Transplantation; 2006 Mar; 81(5):726-35. PubMed ID: 16534475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The replacement of graft endothelium by recipient-type cells conditions allograft rejection mediated by indirect pathway CD4+ T cells.
    Kapessidou Y; Habran C; Buonocore S; Flamand V; Barvais L; Goldman M; Braun MY
    Transplantation; 2006 Aug; 82(4):582-91. PubMed ID: 16958183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An immunodominant minor histocompatibility alloantigen that initiates corneal allograft rejection.
    Haskova Z; Sproule TJ; Roopenian DC; Ksander AB
    Transplantation; 2003 Apr; 75(8):1368-74. PubMed ID: 12717232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of graft-versus-host disease: role of regulatory T lymphocytes.
    Hess AD
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):13-21. PubMed ID: 16399597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [MHC tetramers: tracking specific immunity].
    Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
    Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect allorecognition: not simple but effective.
    Bolton EM; Bradley JA; Pettigrew GJ
    Transplantation; 2008 Mar; 85(5):667-9. PubMed ID: 18337656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Xenotransplantation and ABO incompatible transplantation: the similarities they share.
    Galili U
    Transfus Apher Sci; 2006 Aug; 35(1):45-58. PubMed ID: 16905361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frontline: Peripheral priming of alloreactive T cells by the direct pathway of allorecognition.
    Baratin M; Bonin K; Daniel C
    Eur J Immunol; 2004 Dec; 34(12):3305-14. PubMed ID: 15484192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minor histocompatibility antigens: presentation principles, recognition logic and the potential for a healing hand.
    Spencer CT; Gilchuk P; Dragovic SM; Joyce S
    Curr Opin Organ Transplant; 2010 Aug; 15(4):512-25. PubMed ID: 20616723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.